BioVentrix (BVXX) investor relations material

Company overview and business model

• Focuses on developing, manufacturing, and commercializing proprietary devices for restoring left ventricular function in heart failure patients with reduced ejection fraction (HFrEF).

• Lead product, the Revivent System, is CE marked in Europe and in pivotal U.S. trial; aims to become new standard of care for patients with severe anterior wall scarring post-STEMI.

• Owns rights to Alginate, a hydrogel-based device for HFrEF patients without anterior scarring, expanding addressable market.

• Revenue historically from European sales, currently paused to preserve capital; U.S. commercialization contingent on FDA approval.

Financial performance and metrics

• Reported net losses of $7.7 million in 2025 and $3.9 million in 2024; accumulated deficit of $231.2 million as of December 31, 2025.

• Cash balance of $1.8 million at year-end 2025; negative cash flows from operations of $5.8 million in 2025.

• Operating expenses increased 76% year-over-year, driven by ramp-up for the RELIVE trial and IPO preparation.

• Auditor included a going concern explanatory paragraph due to recurring losses and negative cash flows.

Use of proceeds and capital allocation

• Net proceeds from the IPO will primarily fund the RELIVE clinical trial and associated manufacturing activities (approx. 60%).

• Remaining proceeds allocated to working capital, regulatory compliance, IP protection, and general corporate purposes.

• Additional capital will be required to fully implement business plans and support future product development.